Announced details
Content concerning a company developing novel protein degraders to address unmet medical needs
A consolidated subsidiary of the company
A consolidated subsidiary in the United States. Other details regarding its location, representative, business activities, capital, and year established are Not disclosed.
The materials include statements regarding future business development, the clinical development schedule, and financial targets, but the specific amount of the impact on financial results is Not disclosed.
The company does not address Contract Value / Offering price.
Gyre’s investor website (https://ir.gyretx.com/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Building A New Protein Degrader Company For Unmet Medical Needs |
| Counterparty | Gyre Therapeutics, Inc. |
| Counterparty overview | A consolidated subsidiary in the United States. Other details regarding its location, representative, business activities, capital, and year established are Not disclosed. |
| Relationship with the Company | A consolidated subsidiary of the company |
| Launch date | 26 August 2026, U.S. time (publication of the corporate presentation materials) |
| Applicable area | Content concerning a company developing novel protein degraders to address unmet medical needs |
| Impact on Business Performance | The materials include statements regarding future business development, the clinical development schedule, and financial targets, but the specific amount of the impact on financial results is Not disclosed. |
| Source | Gyre’s investor website (https://ir.gyretx.com/) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Gyre published corporate presentation materials.